Division of Biochemical Toxicology, FDA-National Center for Toxicological Research, Jefferson, AR, USA.
Toxicologic Pathology Associates, Jefferson, AR, USA.
Toxicol Appl Pharmacol. 2024 Oct;491:117046. doi: 10.1016/j.taap.2024.117046. Epub 2024 Jul 29.
Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease, affecting 38% of adults globally. If left untreated, NAFLD may progress to more advanced forms of the disease, including non-alcoholic steatohepatitis (NASH), liver cirrhosis, and fibrosis. Early NAFLD detection is critical to prevent disease progression. Using an obesogenic high-fat and high-sucrose (HF/HS) diet, we characterized the progression of NAFLD in male and female Collaborative Cross CC042 mice after 20-, 40-, and 60-week intervals of chronic HF/HS diet feeding. The incidence and severity of liver steatosis, inflammation, and fibrosis increased in both sexes over time, with male mice progressing to a NASH-like disease state faster than female mice, as indicated by earlier and more pronounced changes in liver steatosis. Histopathological indication of macrovesicular steatosis and gene expression changes of key lipid metabolism genes were found to be elevated in both sexes after 20 weeks of HF/HS diet. Measurement of circulating markers of inflammation (CXCL10 and TNF-α), histopathological analysis of immune cell infiltrates, and gene expression changes in inflammation-related genes indicated significant liver inflammation after 40 and 60 weeks of HF/HS diet exposure in both sexes. Liver fibrosis, as assessed by Picosirius red and Masson's trichrome staining and changes in expression of key fibrosis related genes indicated significant changes after 40 and 60 weeks of HF/HS diet exposure. In conclusion, we present a preclinical animal model of dietary NAFLD progression, which recapitulates human pathophysiological and pathomorphological changes, that could be used to better understand the progression of NAFLD and support development of new therapeutics.
非酒精性脂肪性肝病(NAFLD)是一种进行性肝病,影响全球 38%的成年人。如果不加以治疗,NAFLD 可能会进展为更严重的疾病,包括非酒精性脂肪性肝炎(NASH)、肝硬化和纤维化。早期 NAFLD 的检测对于防止疾病进展至关重要。我们使用致肥胖的高脂肪和高蔗糖(HF/HS)饮食,在雄性和雌性 CC042 协作交叉小鼠中,在慢性 HF/HS 饮食喂养 20、40 和 60 周后,对 NAFLD 的进展进行了描述。随着时间的推移,肝脏脂肪变性、炎症和纤维化的发生率和严重程度在两性中均增加,雄性小鼠进展为 NASH 样疾病状态的速度快于雌性小鼠,这表明肝脏脂肪变性的早期和更明显变化。在 HF/HS 饮食 20 周后,我们发现两性的组织病理学大泡性脂肪变性的指示和关键脂质代谢基因的基因表达变化均升高。在 HF/HS 饮食暴露 40 和 60 周后,通过循环炎症标志物(CXCL10 和 TNF-α)的测量、免疫细胞浸润的组织病理学分析以及炎症相关基因的基因表达变化,表明肝脏炎症显著。在 HF/HS 饮食暴露 40 和 60 周后,通过 Picrosirius 红和 Masson 三色染色以及关键纤维化相关基因表达变化评估肝纤维化,表明发生了显著变化。总之,我们提出了一种饮食性 NAFLD 进展的临床前动物模型,该模型再现了人类的病理生理和形态病理变化,可用于更好地理解 NAFLD 的进展并支持新疗法的开发。